Reactions Weekly

, Volume 1761, Issue 1, pp 162–162 | Cite as

Factor VIII inhibitor bypassing fraction/recombinant factor VIIa

Intra-atrial thrombosis: case report
Case report
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

A 6-year-old boy developed intra-atrial thrombosis during prophylactic treatment with factor VIII inhibitor bypassing fraction and recombinant factor VIIa while on immune tolerance induction [ITI; routes and times to reaction onset not stated].

The boy, who had severe haemophilia A and high-titre inhibitor, had been undergoing ITI with a high dose of efmoroctocog-α [recombinant factor VIII (FVIII; recombinant Fc fusion protein)]. Subsequently, he developed a central venous access device (CVAD)-associated bacteraemia. He had been receiving prophylactic factor VIII inhibitor bypassing fraction [activated prothrombin complex concentrate] 100 units/kg/dose 1−2 times daily along with recombinant factor VIIa 200 μg/kg/dose for breakthrough bleeds through a port CVAD while on ITI....


  1. Weyand AC, et al. Emicizumab prophylaxis to facilitate anticoagulant therapy for management of intra-atrial thrombosis in severe haemophilia with an inhibitor. Haemophilia 25: e203-e205, No. 3, May 2019. Available from: URL: - USA

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations